Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)

Delayed Quote. Delayed  - 07/28 05:35:06 pm
12.255 EUR   -1.01%
07/20 ABLYNX : Announces warrant exercise
07/07 ABLYNX : 07/07/2016 ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM A..
07/07 ABLYNX : ANNOUNCES POSITIVE TOPLINE RESULTS FROM A PHASE IIb STUDY O..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

ABLYNX (D) : RECEIVES EUR 5 MILLION IN MILESTONE PAYMENT FROM ALZHEIMER'S DISEASE COLLABORATION WITH BOEHRINGER INGELHEIM

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/27/2011 | 07:05am CEST

GHENT, Belgium, 27 June 2011 - Ablynx [Euronext Brussels: ABLX] today announced that it has earned a ?5 million milestone payment following Boehringer Ingelheim's decision to initiate development  with the lead Nanobody candidate that was selected in May 2010.

 

In January 2007, Boehringer Ingelheim and Ablynx announced a worldwide research and licensing agreement to discover and develop new therapies for Alzheimer's disease using Ablynx's Nanobodies against a single disease target. The collaboration has a potential value of $265 million in upfront and milestone payments plus undisclosed royalties on product sales. Boehringer Ingelheim is solely responsible for the development, manufacturing and commercialisation of any products resulting from the collaboration.

 

"We are delighted that Boehringer Ingelheim is making further progress with the Nanobody lead candidate which has the potential to be a first-in-class therapy for Alzheimer's disease and we look forward to this product advancing into the clinic in 2012. This is the second milestone payment that we have received as part of our Alzheimer's research collaboration with Boehringer Ingelheim," said Dr. Edwin Moses, Chairman and CEO of Ablynx. He added: "This programme illustrates the wide applicability and advantages of our Nanobody platform in addressing diseases as complex as Alzheimer's."

 

 

For more information, please contact Ablynx:
Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com:
mailto:edwin.moses@ablynx.com

 

Marieke Vermeersch
Investor Relations Manager
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch@ablynx.com :
mailto:marieke.vermeersch@ablynx.com%20

 

Complete version of the press release:
http://hugin.info/137912/R/1526010/461786.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Ablynx via Thomson Reuters ONE

HUG#1526010
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABLYNX
07/20 ABLYNX : Announces warrant exercise
07/07 ABLYNX : 07/07/2016 ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM A PHASE IIb S..
07/07 ABLYNX : ANNOUNCES POSITIVE TOPLINE RESULTS FROM A PHASE IIb STUDY OF ITS ANTI-I..
07/04 VECTURA : Licence Option Exercised
07/01 ABLYNX : 03/06/2016 ablynx to present at the annual jefferies healthcare confere..
06/28 VECTURA : Says Partner Ablynx Exercises Commercial Licence Option
06/17 ABLYNX : 16/06/2016 correction transparency notification - adrianus van herk ann..
06/16 ABLYNX : Correction transparency notification - adrianus van herk announces 3.02..
06/16 ABLYNX : 16/06/2016 van herk investments announce 3.02% shareholding in ablynx
06/16 ABLYNX : Van herk investments announce 3.02% shareholding in ablynx
More news
Sector news : Biotechnology & Medical Research - NEC
07/28DJCELGENE : Lifts Guidance as Revlimid Sales Rise -- Update
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
07/28DJCELGENE : Lifts Guidance as Revlimid Sales Rise
07/27DJVERTEX PHARMACEUTICALS : Pharma Loss Narrows as Cystic Fibrosis Drug Sales Grow
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
07/07 Ablynx's vobarilizumab shows positive treatment effect in mid-stage arthritis..
05/08 Ablynx's (ABLYF) CEO Edwin Moses on Results from first-in-infant study with i..
04/12 How AbbVie Plans To Replace Humira
02/27 Ablynx's (ABLYF) CEO Edwin Moses on Q4 2015 Results - Earnings Call Transcrip..
02/25 Ablynx NV reports FY15 results
Advertisement
Financials (€)
Sales 2016 100,0 M
EBIT 2016 -8,32 M
Net income 2016 -4,75 M
Finance 2016 39,1 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 7,15x
EV / Sales 2017 16,1x
Capitalization 754 M
More Financials
Chart ABLYNX
Duration : Period :
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Full-screen chart
Technical analysis trends ABLYNX
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 18,0 €
Spread / Average Target 45%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Edwin Moses Chief Executive Officer & Director
Peter John Fellner Chairman
Kim Simonsen Chief Operations Officer
Wim Ottevaere Chief Financial Officer
Antonin Rollet de Fougerolles Chief Scientific Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX-22.23%835
INCYTE CORPORATION-18.75%16 646
CELLTRION, INC.--.--%10 582
LONZA GROUP AG12.20%9 818
QUINTILES TRANSNATIONA..13.49%8 975
ALKERMES PLC-39.37%7 827
More Results